301MO Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy

Authors
Publication date
1 January 2020
Publisher
Elsevier Inc.

Abstract

We aimed to assess the role of genomic HLA-I/II homozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non-small lung cancer treated by single agent PD1/PDL1 inhibitors..

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Research Repository

    redirect
    oaioai:researchrepository.murdoch...
    Last time updated on 08/04/2021